Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial

• Published in: Journal of hepatology Vol. 68; no. 6; pp. 1163 - 1171
• Main Authors: Guiu, Boris, Jouve, Jean-Louis, Schmitt, Antonin, Minello, Anne, Bonnetain, Franck, Cassinotto, Christophe, Piron, Lauranne, Cercueil, Jean-Pierre, Loffroy, Romaric, Latournerie, Marianne, Wendremaire, Maëva, Lepage, Côme, Boulin, Mathieu
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2018; Elsevier Science Ltd
• Subjects: Chemolipiodolisation; Clinical trials; Cytotoxicity; Drug therapy; Embolisms; Hepatocellular carcinoma; Idarubicin; Intravenous administration; Liver cancer; Pain; Patients; Pharmacokinetics; Phase I; Quality of life; Safety; Solid tumors; Chemolipiodolisation; Hepatocellular carcinoma; Idarubicin; Phase I

[Display omitted] •The maximum-tolerated dose (MTD) of idarubicin was 20 mg after two chemolipiodolisation sessions.•Intra-arterial idarubicin_lipiodol was well tolerated.•Intra-arterial idarubicin_lipiodol showed encouraging responses and survival.•Health-related quality of life results confirmed t...